HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Givaudan

This article was originally published in The Rose Sheet

Executive Summary

Fragrance division revenues advanced 3.3% in local currencies, or 2.8% in Swiss francs, to $664.3 mil. (CHF1=$.78) for the nine month period, flavors and fragrances company announces. Despite a number of new launches, particularly in North America, fine fragrances business continued to perform below last year's level, firm notes. Consumer products sales within the fragrance division outperformed the market, with double-digit growth in North America, although fragrance ingredient sales were below the prior year level. Givaudan net sales during the period were up 1.6% in local currencies, or 1% in Swiss francs, to $1.63 bil., firm adds...

You may also be interested in...



Roche's Tecentriq Disappoints In Ovarian Cancer Study

PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.

Greater Uptake Must Become Belgium’s ‘New Normal’

Increased uptake for generics and biosimilars must become Belgium’s “new normal” in the wake of the coronavirus crisis, local off-patent industry association Medaxes has argued.

Biologicals Join List Of EU Medicines Requiring Nitrosamine Evaluation

Although biological medicines carry a very low risk of being contaminated by nitrosamine impurities, the EMA says the possibility cannot be ruled out.

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel